Skip to main content
SpringerLink
Log in

Antibody-Toxin Conjugates

Chemistry of Coupling and Purification

  • Chapter
Tumor Targeting in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 256 Accesses

Abstract

Soon after their discovery (1), monoclonal antibodies (MAbs) were exploited for their targeting specificity to deliver cytotoxic moieties, such as protein toxins, enzymes that activate prodrugs in situ, chemotherapeutic agents, and radionuclides. Many of this first-class generation of protein-protein conjugates, presented chemists with the challenge of designing a linker that is easily cleaved intracellularly but sufficiently stable in the blood circulation, and of developing purification procedures for obtaining highly active preparations suitable for clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 246:495–497.

    Article  Google Scholar 

  2. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, et al. Evaluation of a CD5specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88:824–830.

    PubMed  CAS  Google Scholar 

  3. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999; 11:570–578.

    Article  PubMed  CAS  Google Scholar 

  4. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6:326–334.

    PubMed  CAS  Google Scholar 

  5. O’Toole JE, Esseltine D, Lynch TJ, Lambert JM, Grossbard ML. Clinical trials with blocked ricin immunotoxins. Curr Top Microbiol Immunol 1998; 234:35–56.

    Article  PubMed  Google Scholar 

  6. Flavell DJ. Saporin immunotoxins. Curr Top Microbiol Immunol 1998; 234:57–61.

    Article  PubMed  CAS  Google Scholar 

  7. Bjorn MJ, Groetsema G, Scalapino L. Antibody-Pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 1986; 46:3262–3267.

    PubMed  CAS  Google Scholar 

  8. Fitzgerald D, Idziorek T, Batra JK, Willingham M, Pastan I. Antitumor activity of a thioether-linked immunotoxin: OVB3-PE. Bioconjugate Chem 1990; 1:264–268.

    Article  CAS  Google Scholar 

  9. Houston LL, Nowinski RC. Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against thy 1.1 antigen. Cancer Res 1981; 41:3913–3917.

    PubMed  CAS  Google Scholar 

  10. Zovickian J, Johnson VG, Youle RJ. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Neurosurgery 1987; 66:850–861.

    Article  CAS  Google Scholar 

  11. Kobayashi H, Kao CH, Kreitman RJ, Le N, Kim MK, Brechbiel MW, et al. Pharmacokinetics of 1 11Inand 125I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med 2000; 41:755–762.

    PubMed  CAS  Google Scholar 

  12. Thorpe PE, Ross WC, Brown AN, Myers CD, Cumber AJ, Foxwell BM, Forrester JT. Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. Eur Biochem 1984; 140:63–71.

    Article  CAS  Google Scholar 

  13. Wawrzynczak EJ, Watson GJ, Cumber AJ, Henry RV, Parnell GD, Rieber EP, Thorpe PE. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. Cancer Immunol Immunother 1991; 32:289–295.

    Article  PubMed  CAS  Google Scholar 

  14. Brusa P, Dosio F, Pietribiasi F, Delprino L, Feraiorni P, Mariani M, Bussolati G, Cattel L. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice. Cancer Immunol Immunother 1992; 35:373–380.

    Article  PubMed  CAS  Google Scholar 

  15. Pietersz GA, Kanellos J, McKenzie IF. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity. Cancer Res 1988; 48:4469–4476.

    PubMed  CAS  Google Scholar 

  16. Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 1991; 30:3234–3247.

    Article  PubMed  CAS  Google Scholar 

  17. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown ANF, Watson GJ, et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res 1987: 47:5924–5931.

    PubMed  CAS  Google Scholar 

  18. Cumber AJ, Westwood JH, Henry RV, Parnell GD, Coles BF, Wawrzynczak, EJ. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins. Bioconjugate Chem 1992; 3:397–401.

    Article  CAS  Google Scholar 

  19. Ghetie V, Till MA, Ghetie MA, Tucker T, Porter J, Patzer EJ, et al. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers. Bioconjugate Chem 1990; 1:24–31.

    Article  CAS  Google Scholar 

  20. Vallera DA, Bums LJ, Frankel AE, Sicheneder AR, Gunther R, Gajl-Peczalska K, et al. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J Immunol Methods 1996; 197:69–83.

    Article  PubMed  CAS  Google Scholar 

  21. Flavell DJ, Boehm DA, Okayama K, Kohler JA, Flavell SU. Therapy of human T cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers. Intl J Cancer 1994; 58:407–414.

    Article  CAS  Google Scholar 

  22. Greenfield L, Bloch W, Moreland M. Thiol-containing cross-linking agent with enhanced steric hindrance. Bioconjugate Chem 1990; 1:400–410.

    Google Scholar 

  23. Goff DA, Carroll SF. Substituted 2-iminothiolanes: reagents for the preparation of disulfide crosslinked conjugates with increased stability. Bioconjugate Chem 1990; 1:381–386.

    Article  CAS  Google Scholar 

  24. Carroll SF, Bernhard SL, Goff DA, Bauer RJ, Leach W, Kung AHC. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane. Bioconjugate Chem 1994; 5:248–256.

    Article  CAS  Google Scholar 

  25. Dosio F, Brusa P, Delprino L, Ceruti M, Grosa G, Cattel L, et al. A new ‘solid phase’ procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates). Farmaco 1993; 48:105–115.

    PubMed  CAS  Google Scholar 

  26. Delprino L, Giacomotti M, Dosio F, Brusa P, Ceruti M, Grosa G, Cattel L. Toxin-targeted design for anticancer therapy. II: preparation and biological comparison of different chemically linked geloninantibody conjugates. J Pharmaceut Sci 1993; 82:699–704.

    Article  CAS  Google Scholar 

  27. Arpicco S, Dosio F, Brusa P, Crosasso P, Cattel L. New coupling reagents for the preparation of disulfide cross-linked coniugates with increased stability. Bioconjugate Chem 1997: 8:327–337.

    Article  CAS  Google Scholar 

  28. Dosio F, Arpicco S, Adobati E, Canevari S, Brusa P, De Santis R, et al. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. Bioconjugate Chem 1998; 9:372–381.

    Article  CAS  Google Scholar 

  29. Blattier WA, Lambert JM, Senter PD. Acid-cleavable compound. US Patent 1984; 454:2225.

    Google Scholar 

  30. McIntyre GD, Scott CFJ, Ritz J, Blattler WA, Lambert JM. Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjugate Chem 1994; 5:88–97.

    Article  CAS  Google Scholar 

  31. Neville DMJ, Srinivasachar K, Stone R, Scharff J. Enhancement of immunotoxin efficacy by acidcleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J. Biol Chem 1989; 264:14653–14661.

    PubMed  CAS  Google Scholar 

  32. Wellhoner HH, Neville DMJ, Srinivasachar K, Erdmann G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J Biol Chem 1991; 266:4309–4314.

    PubMed  CAS  Google Scholar 

  33. Srinivasachar K, Neville DM, Jr. New protein cross-linking reagents that are cleaved by mild acid. Biochemistry 1989; 28:2501–2509.

    Article  PubMed  CAS  Google Scholar 

  34. Marsh JW, Neville DM, Jr. A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins. J Immunol 1988; 140:3674–3678.

    PubMed  CAS  Google Scholar 

  35. Akerblom E, Dohlsten M, Bryno C, Mastej M, Steringer I, Hedlund G, et al. Preparation and characterization of conjugates of monoclonal antibodies and staphylococcal enterotoxin A using a new hydrophilic cross-linker. Bioconjugate Chem 1993; 4:455–466.

    Article  CAS  Google Scholar 

  36. Woo BH, Lee JT, Park MO, Lee KR, Han JW, Park ES, et al. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents. Arch Pharm Res 1999; 22:459–463.

    Article  PubMed  CAS  Google Scholar 

  37. Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling, JJ, et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem 1989; 32:548–555.

    Article  PubMed  CAS  Google Scholar 

  38. Petersen BH, Barrett P, Labus J, Woodworth J, Zimmermann J, Butler F, Dugan W, Schneck DW. Murine monoclonal antibody-vinca conjugates KS 1 /4-DAVLB hydrazine: phase 1 studies in patients with adenocarcinoma. Antibody Immunoconj Radiopharmacol 1993; 6:127–139.

    Google Scholar 

  39. Kralovec J, Spencer G, Blair AH, Mammen M, Singh M, Ghose T. Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities. J Med Chem 1989; 32:2426–2431.

    Article  PubMed  CAS  Google Scholar 

  40. Zara JJ, Wood RD, Boon P, Kim CH, Pomato N, Bredehorst R, Vogel CW. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates. Anal Biochem 1991; 194:156–162.

    Article  PubMed  CAS  Google Scholar 

  41. Zara J, Pomato N, McCabe RP, Bredehorst R, Vogel CW. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjugate Chem 1995; 6:367–372.

    Article  CAS  Google Scholar 

  42. Flavell DJ, Boehm DA, Noss A, Flavell SU. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule. Br J Cancer 1997; 75:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  43. Dosio F, Arpicco S, Canevari S, Figini M, Gastaldi D. Single step purification of immunotoxins containing a high ionic charge ribosome inactivating protein clavin by carboxymethyl high performance membrane chromatography. J Chromatogr 1999; 830:329–335.

    Article  CAS  Google Scholar 

  44. Lambert JM, Senter PD, Yau-Young A, Blatter WA, Goldmacher VS. Purified immunotoxins that are reactive with human lymphoid cells: Monoclonal antibodies conjugated to the ribosome inactivating proteins gelonin and pokeweed antiviral protein. J Biol Chem 1985; 260:12035–12041.

    PubMed  CAS  Google Scholar 

  45. Cumber AJ, Henry RV, Parnell GD, Wawrzynczak EJ. Purification of immunotoxins containing the ribosome-inactivating proteins gelonin and momordin using high performance liquid immunoaffinity chromatography compared with Blue Sepharose CL-6B affinity chromatography. J Immunol Methods 1990; 135:15–24.

    Article  PubMed  CAS  Google Scholar 

  46. Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR. A gelonin-containing immunotoxin directed against human breast carcinoma. Mol Biotherapy 1992; 4:122–129.

    CAS  Google Scholar 

  47. Knowles PP, Thorpe PE. Purification of immunotoxins containing ricin A chain and abrin A chain using Blue Sepharose CL-6B. Anal Biochem 1987; 160:440–446.

    Article  PubMed  CAS  Google Scholar 

  48. Ghetie V, Till MA, Ghetie MA, Uhr JW, Vitetta ES. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. J Immunol Methods 1990; 126:135–141.

    Article  PubMed  CAS  Google Scholar 

  49. Dhanabal M, Fryxell DK, Ramakrishnan S. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins. J Immunol Methods 1995; 182:165–175.

    Article  PubMed  CAS  Google Scholar 

  50. D’Alatri L, Di Massimo AM, Anastasi AM, Pacilli A, Novelli S, Saccinto MP, De Santis R, Mele A, Parente D. Production and characterisation of a recombinant single-chain anti ErbB2-clavin immunotoxin. Anticancer Res 1998; 18:3369–3373.

    PubMed  Google Scholar 

  51. Ferris R, Laird WI. Method of purifying toxin conjugates using hydrophobic interaction chromotography. US Patent 1988; 477:1128.

    Google Scholar 

  52. Ferris R. One-step chromatographic purification of immunotoxin conjugates using thiophilic matrix. WO Patent 1989; 891:1871.

    Google Scholar 

  53. Meyer BF, Stoner ML, Raphael CL, Davis RE, Herrmann RP. Streptavidin-biotin immunotoxins: A new approach to purging bone marrow. Exp Hematol 1991; 19:710–713.

    PubMed  CAS  Google Scholar 

  54. Dosio F, Brusa P, Crosasso P, Fruttero C, Cattel L, Bolognesi A. Synthesis of different immunotoxins composed by ribosome inactivating proteins non-covalently bound to monoclonal antibody. Farmaco 1996; 51:477–482.

    PubMed  CAS  Google Scholar 

  55. Ferrini S, Sforzini S, Canevari S. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins, in Methods in Molecular Biology Series 2001, vol 166; Immunotoxin methods and protocols (Hall, WA, ed). Humana Press, Totowa, NJ, 2000, pp. 177–179.

    Chapter  Google Scholar 

  56. Fitzgerald D, Pastan I, Robertus J. Clinical applications of immunotoxins. Introduction. Cur Top Microbiol Immunol 1998; 234:1–11.

    Article  CAS  Google Scholar 

  57. Oldfield EH, Youle RJ. Immunotoxins for brain tumor therapy. Curr Top Microbiol Immunol 1998; 234:97–114.

    Article  PubMed  CAS  Google Scholar 

  58. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nature Med 1997; 3:1362–1368.

    Article  PubMed  CAS  Google Scholar 

  59. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999; 96:3957–3962.

    Article  PubMed  CAS  Google Scholar 

  60. Thorpe PE, Brown AN, Ross WC, Cumber AJ, Detre SI, Edwards DC, Davies AJ, Stirpe E Cytotoxicity acquired by conjugation of an anti-Thy 1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. Eur J Biochem 1981; 116:447–454.

    Article  PubMed  CAS  Google Scholar 

  61. Uckun FM. Immunotoxins for the treatment of leukaemia. Br J Haematol 1993; 85:435–438.

    Article  PubMed  CAS  Google Scholar 

  62. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, et al. Response of refractory Hodgkin’s disease to monoclonal anti- CD30 immunotoxin. Lancet 1992; 339:1195–1196.

    Article  PubMed  CAS  Google Scholar 

  63. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, et al. Phase I immunotoxin trial in patients with Bcell lymphoma. Cancer Res 1991; 51:4052–4058.

    PubMed  CAS  Google Scholar 

  64. Grossbard ML, Multani PS, Freedman AS, O’Day S, Gribben JG, Rhuda C, et al. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 1999; 5:2392–2398.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Silvana Canevari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Ines Colnaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luigi Cattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franco Dosio
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Biology, Faculty of Medicine, Université Laval, Sainte-Foy, Québec, Canada

    Michel Pagé PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Canevari, S., Colnaghi, M.I., Cattel, L., Dosio, F. (2002). Antibody-Toxin Conjugates. In: Pagé, M. (eds) Tumor Targeting in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-167-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-167-1_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-251-3

  • Online ISBN: 978-1-59259-167-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation